Nasdaq · CIK 0001196298
NEPH NEPHROS INC
Insider trading from SEC Form 4. Last filing 27 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at NEPHROS INC, scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Wexford Capital LP owner | JOther Common Stockindirect: See footnotes | -3,355,111 | $0.00 | $0 | 189,377 | 27 d ago |
| Sep 14, 2026 | Arthur H Amron director | JOther Common Stock | +17,749 | $0.00 | $0 | 158,623 | 27 d ago |
| Sep 14, 2026 | Arthur H Amron director | JOther Common Stockindirect: See footnote | +2,836 | $0.00 | $0 | 2,836 | 27 d ago |
| Sep 14, 2026 | Wexford Capital LP owner | JOther Common Stockindirect: See footnotes | -22,710 | $3.95 | $90k | 166,667 | 27 d ago |
| Sep 14, 2026 | Arthur H Amron director | JOther Common Stockindirect: See footnote | +22,710 | $3.95 | $90k | 25,546 | 27 d ago |
| May 11, 2026 | Arthur H Amron director | AGrant or award Common Stock | +3,574 | $0.00 | $0 | 138,456 | Jun 12, 2026 |
| Mar 23, 2026 | Robert R. Banks Jr. President and CEO | MOption exercise Common Stock | +120,000 | $1.44 | $173k | 190,000 | Mar 25, 2026 |
| Mar 23, 2026 | Judy Krandel Chief Financial Officer | MOption exercise Common Stock | +68,861 | $1.71 | $118k | 68,861 | Mar 25, 2026 |
| Mar 23, 2026 | Robert R. Banks Jr. President and CEO | MOption exercise Stock Option (right to buy)derivative | -120,000 | $0.00 | $0 | 237,165 | Mar 25, 2026 |
| Mar 23, 2026 | Judy Krandel Chief Financial Officer | MOption exercise Stock Option (right to buy)derivative | -68,861 | $0.00 | $0 | 53,663 | Mar 25, 2026 |
| Mar 16, 2026 | Arthur H Amron director | AGrant or award Common Stock | +3,610 | $0.00 | $0 | 134,882 | Mar 18, 2026 |
| Mar 16, 2026 | Judy Krandel Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +4,000 | $0.00 | $0 | 4,000 | Mar 18, 2026 |
| Nov 10, 2025 | Arthur H Amron director | AGrant or award Common Stock | +5,391 | $0.00 | $0 | 131,272 | Nov 13, 2025 |
| Nov 10, 2025 | Oliver J. Spandow director | AGrant or award Common Stock | +8,036 | $0.00 | $0 | 122,881 | Nov 13, 2025 |
| Nov 10, 2025 | Lisa Marie Nettis director | AGrant or award Common Stock | +1,622 | $0.00 | $0 | 1,622 | Nov 13, 2025 |
| Aug 11, 2025 | Lisa Marie Nettis director | AGrant or award Stock Option (right to buy)derivative | +13,229 | $0.00 | $0 | 13,229 | Aug 13, 2025 |
| Mar 27, 2025 | Judy Krandel Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +54,359 | $0.00 | $0 | 54,359 | Mar 31, 2025 |
| Jan 1, 2025 | Arthur H Amron director | AGrant or award Common Stock | +22,418 | $0.00 | $0 | 125,881 | Jan 3, 2025 |
| Jan 1, 2025 | Arthur H Amron director | AGrant or award Stock Option (Right to Buy)derivative | +7,050 | $0.00 | $0 | 7,050 | Jan 3, 2025 |
| Jan 1, 2025 | Joseph Michael Harris director | AGrant or award Stock Option (right to buy)derivative | +7,050 | $0.00 | $0 | 7,050 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Arthur H Amrondirector
- Robert R. Banks Jr.President and CEO
- Joseph Michael Harrisdirector
- Judy KrandelChief Financial Officer
- Lisa Marie Nettisdirector
- Oliver J. Spandowdirector
- Wexford Capital LPowner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.